---
document_datetime: 2026-02-19 14:09:18
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kigabeq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kigabeq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5050005
conversion_datetime: 2026-02-21 12:53:22.118921
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Kigabeq

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 18/02/2026                          |                                             | Labelling and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | Update of the package leaflet with revised contact details of local representatives and update of the MAH address in section '11. Name and address of the marketing authorisation holder' of the 'Particulars to appear on immediate packaging' for Kigabeq 500 mg in the labelling. Additionally, the MAH took the opportunity to introduce minor corrections in all language versions.   |            | PL   | EMA/N/0000327681   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|--------------------|
| Variation type IB / EMA/VR/0000284408 | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted                                                                                                                                                                                                                                 | 18/07/2025 |      |                    |